Skip to main content

Displaying 11 - 20 of 25

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Bladder, Colon, Esophageal, Gastric/Gastroesophageal, Head/Neck, Kidney (Renal Cell), Lung, Ovarian, Pancreatic, Urologic
I/II
Berlin, Jordan
NCT04895709
VICC-DTPHI23183

A Randomized Trial of Neratinib, a PAN-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

Multiple Cancer Types

Bladder, Cervical, Colon, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Head/Neck, Liver, Lung, Non Small Cell, Ovarian, Rectal, Urologic, Uterine
II
Choe, Jennifer
NCT06126276
ECOGMDEAY191-N5

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Multiple Cancer Types

Breast, Gastrointestinal, Gynecologic, Head/Neck, Lung, Melanoma, Neuro-Oncology, Sarcoma, Urologic
II
Choe, Jennifer
NCT05564377
VICC-NTMDT23238

Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis [PROMISE Trial]

Head/Neck

Head/Neck
N/A
Murphy, Barbara
NCT06125743
VICC-EDHAN23569

Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Head/Neck

Head/Neck
II
Rosenthal, Eben
NCT04511078
VICCHN21109

Placebo-Controlled Phase II Randomized Clinical Trial of Photobiomodulation Therapy in Head and Neck Cancer Survivors with Chronic Lymphedema

Head/Neck

Head/Neck
II
Murphy, Barbara
NCT06837480
VICCHN25039




Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Multiple Cancer Types

High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-IRDye800 (nivo800) which incorporates a near-infrared (NIR) fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.
Head/Neck, Neuro-Oncology
N/A
Kelly, Patrick
NCT07210632
VICCHN25046